{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:38Z","timestamp":1792831058828,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02375-1","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:18:50Z","timestamp":1787141930000},"page":"1913-1918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Andamertinib: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"33","key":"2375_CR1","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1111\/1759-7714.15127","volume":"14","author":"B Pan","year":"2023","unstructured":"Pan B, Liang J, Shi H, et al. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer. Thorac Cancer. 2023;14(33):3247\u201358.","journal-title":"Thorac Cancer"},{"key":"2375_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115917","author":"D Seo","year":"2024","unstructured":"Seo D, Lim JH. Targeted therapies for EGFR exon 20 insertion mutation in non-small-cell lung cancer. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115917.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2375_CR3","doi-asserted-by":"publisher","first-page":"103540","DOI":"10.1016\/j.jtho.2025.12.079","volume":"21","author":"MH Wu","year":"2026","unstructured":"Wu MH, Huang DD. Decoding variants in EGFR exon 20 insertions: guiding therapy beyond a one-size-fits-all approach. J Thorac Oncol. 2026;21(3):103540.","journal-title":"J Thorac Oncol"},{"key":"2375_CR4","unstructured":"Anshi Biotechnology. Anshi Biotechnology's brerutinib and andatinib (PLB1004) capsules have been recognized as CDE breakthrough therapy [media release]. 17 Apr 2025. http:\/\/www.avistonebio.com."},{"key":"2375_CR5","unstructured":"Beijing Avistone Biotechnology. Anshi Biosciences' NDA application for andatinib benzoate capsules (PLB1004 capsules) has been formally accepted and included in the priority review process [media release]. 22 May 2025. http:\/\/www.avistonebio.com."},{"key":"2375_CR6","unstructured":"Beijing Avistone Biotechnology. Avistone Biotechnology-\u5b89\u6bd4\u9510\u00ae (andamertinib) approved in China for EGFR exon 20 insertion mutated NSCLC [media release]. 30 Apr 2026. https:\/\/en.avistonebio.com\/news_details\/129.html."},{"key":"2375_CR7","unstructured":"Beijing Avistone Biotechnology. Andamertinib benzoate capsule \u82ef\u7532\u9178\u5b89\u8fbe\u827e\u66ff\u5c3c\u80f6\u56ca (\u5b89\u6bd4\u9510\u00ae): Chinese prescribing information (machine translated). 2026. https:\/\/en.avistonebio.com\/science_product.html. Accessed 22 July 2026."},{"issue":"1","key":"2375_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00280-024-04744-7","volume":"95","author":"D Liu","year":"2025","unstructured":"Liu D, Li Q, Yan S, et al. Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans. Cancer Chemother Pharmacol. 2025;95(1):19.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2375_CR9","doi-asserted-by":"publisher","first-page":"103518","DOI":"10.1016\/j.jtho.2025.11.008","volume":"21","author":"JJ Yang","year":"2026","unstructured":"Yang JJ, Mu Y, Wang ZH, et al. Andamertinib in advanced NSCLC with EGFR exon 20 insertions after platinum-based chemotherapy or immunotherapy: results from the phase 2 KANNON study. J Thorac Oncol. 2026;21(3):103518.","journal-title":"J Thorac Oncol"},{"issue":"16 Suppl","key":"2375_CR10","doi-asserted-by":"publisher","first-page":"8632","DOI":"10.1200\/JCO.2025.43.16_suppl.8632","volume":"43","author":"F Zhou","year":"2025","unstructured":"Zhou F, Ren S, Che G, et al. Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: a phase Ib\/II study [abstract]. J Clin Oncol. 2025;43(16 Suppl):8632.","journal-title":"J Clin Oncol"},{"key":"2375_CR11","doi-asserted-by":"crossref","unstructured":"Yang JJ, Wu YL, Huang MJ, et al. Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung cancer [abstract no. CT102]. Cancer Res. 2023;83(8_Suppl).","DOI":"10.1158\/1538-7445.AM2023-CT102"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02375-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:11:55Z","timestamp":1792829515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02375-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02375-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"12 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}